Somnolence Associated with Risperidone Therapy in a 91-Year-Old Woman

Leyson JE Gommeren W Eens A :Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 247:661–670,1988.

Cohen LJ :Risperidone. Pharmacotherapy 14:253–265,1994.

Marder SR Meibach RC :Risperidone in the treatment of schizophrenia. Am J Psychiatry 151:825–835,1994.

Chouinard G Jones B Remington G :A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacology 13:25–40,1993.

Ereshefsky L Lacombe S :Pharmacological profile of risperidone. Can J Psychiatry 38:S80–S88, 1993 (suppl 3).

Grant S Fitton A :Risperidone: A review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs 48:253–273,1994.

Huang ML Van Peer A Woestenborghs R :Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 54:257–268,1993.

Borison RL Diamond B Pathiraja A :Pharmacokinetics of risperidone in chronic schizophrenic patients. Psychopharmacol Bull 30:193–197,1994.

Heykants J Huang ML Mannens G :The Pharmacokinetics of risperidone in humans: A summary. J Clin Psychiatry 55:13–17,1994 (May suppl).

Janssen Pharmaceutica, Risperdal® package insert, Titusville, NJ, 1994.

Evans WE Relling MV Rahman A :Genetic basis for a lower prevalence of deficient CYP2 DC oxidative drug metabolism phenotypes in Black Americans. J Clin Invest 91:2150–2154,1993.

Mannens G Huang ML Meuldermans W :Absorption, metabolism, and excretion of risperidone in humans. Drug Metabol Disposition 21:1134–1141,1993.

Snoeck E Van Peer A Sack M : Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Clinical Pharmacological Meeting, Utrecht, The Netherlands, April 2, 1993.

Mannens G Meuldermans W Snoeck E :Plasma protein binding of risperidone and its distribution in blood. Psychopharmacology 114:566–572,1994.

Webster P Wijerathe C :Risperidone-induced neuroleptic malignant syndrome. Lancet 344:1228–1229,1994.